CN115337410A - Tissue staining agent for endoscopic screening of canceration and preparation method thereof - Google Patents
Tissue staining agent for endoscopic screening of canceration and preparation method thereof Download PDFInfo
- Publication number
- CN115337410A CN115337410A CN202211057928.4A CN202211057928A CN115337410A CN 115337410 A CN115337410 A CN 115337410A CN 202211057928 A CN202211057928 A CN 202211057928A CN 115337410 A CN115337410 A CN 115337410A
- Authority
- CN
- China
- Prior art keywords
- tissue
- parts
- stain
- tissue stain
- iodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012216 screening Methods 0.000 title claims abstract description 21
- 238000010186 staining Methods 0.000 title abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 239000012859 tissue stain Substances 0.000 claims abstract description 63
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 42
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 42
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 42
- 239000011630 iodine Substances 0.000 claims abstract description 30
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 30
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 36
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical group [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000009518 sodium iodide Nutrition 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 150000002496 iodine Chemical class 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 15
- 230000000638 stimulation Effects 0.000 abstract description 6
- 230000007794 irritation Effects 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 36
- 238000010586 diagram Methods 0.000 description 30
- 210000003238 esophagus Anatomy 0.000 description 22
- 210000001156 gastric mucosa Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000012472 biological sample Substances 0.000 description 18
- 238000005303 weighing Methods 0.000 description 18
- 230000003902 lesion Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 9
- 201000004101 esophageal cancer Diseases 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 7
- 239000000975 dye Substances 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 229920002527 Glycogen Polymers 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- -1 colloid protection Chemical class 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000227425 Pieris rapae crucivora Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the technical field of disease screening, in particular to a tissue staining agent for endoscopic screening of canceration and a preparation method thereof. The tissue stain includes: 1 to 4 parts of polyvinylpyrrolidone iodine and 0.5 to 1 part of iodized salt. The invention solves the problem of strong irritation of the tissue staining agent in the prior art. The tissue staining agent has the advantages of wide applicable patient population, high effectiveness, simplicity in operation, high safety and small stimulation.
Description
Technical Field
The invention relates to the technical field of disease screening, in particular to a tissue staining agent for endoscopic screening of canceration and a preparation method thereof.
Background
Esophageal cancer is one of the most common malignant tumor diseases in China and is also a high-incidence malignant tumor in the world. Early esophageal cancer has no obvious clinical manifestation, most of the esophageal cancer is in the middle and late stages when symptoms appear, patients in the early stage and without clinical manifestation can be found through routine gastroscopy, and the incidence rate and the fatality rate of esophageal cancer can be reduced through timely intervention or treatment. The diagnosis of early esophageal cancer is therefore particularly important. More than 90% of esophageal cancer in China is squamous cell carcinoma, and early Esophageal Squamous Cell Carcinoma (ESCC) refers to squamous cell carcinoma limited to mucosal layer.
At present, common endoscope inspection techniques for early cancer include common white light endoscopes, pigment endoscopes, electronic pigment endoscopes, magnifying endoscopes, confocal laser microscopy and the like. The pigment endoscope is characterized in that various dyes are scattered or sprayed on the surface of esophageal mucosa, so that the color of a focus is clearly contrasted with that of a normal mucosa, the focus range can be more clearly displayed, and indicative biopsy is convenient to carry out.
The iodine stain (Lugol's liquid) which is clinically used most frequently at present has the advantages of fast color development and clear boundary, and the basic principle is that iodine simple substance reacts with glycogen particles in esophageal squamous epithelium to form brown tea color, while cancer epithelium and intraepithelial neoplasia epithelium contain little glycogen to form light stain or no stain, thereby forming contrast (the specific effect is referred to as figure 1 below). However, iodine staining agents have many adverse reactions including hypersensitivity, gum swelling, sore throat burning, stomach discomfort or vomiting and diarrhea. Therefore, the research and development of the stain which is suitable for wide patient population, high in effectiveness, simple to operate, high in safety and small in stimulation is of great clinical significance for early esophageal cancer screening.
Disclosure of Invention
The invention relates to a tissue stain for endoscopic screening in canceration and a preparation method thereof, and solves the problem of poor safety of the tissue stain in the prior art. The tissue staining agent has the advantages of wide applicable patient population, high effectiveness, simplicity in operation, high safety and small stimulation.
The invention provides a tissue stain for endoscopic screening of canceration, which comprises the following components in parts by weight: 1 to 4 parts of polyvinylpyrrolidone iodine and 0.5 to 1 part of iodized salt.
Polyvinylpyrrolidone (PVP) is a non-ionic polymeric compound that has been widely used due to its excellent unique properties. PVP is a synthetic water-soluble polymer compound, and has the general properties of a water-soluble polymer compound, such as colloid protection, film-forming property, cohesiveness, hygroscopicity, solubilization or coacervation. PVP has excellent physiological inertia, does not participate in human metabolism, has excellent biocompatibility and does not cause any stimulation to skin, mucous membrane, eyes and the like. The pharmaceutical grade PVP is one of three new medicinal auxiliary materials advocated internationally, and can be used as a binder for tablets and granules, a cosolvent for injection and a glidant for capsules; antidotes for eye drugs, retarding agents, lubricants, film-forming coating agents, dispersants for liquid preparations, stabilizers for enzymes and heat-sensitive drugs, and cryopreservative agents. PVP is widely used as an adjuvant for pharmaceutical preparations. In addition, PVP has good food safety, can form a complex with a specific polyphenol compound (such as tannin), and is mainly used as a food clarifying agent and a stabilizing agent for beer, fruit juice, wine and the like in the aspect of food processing. In synthetic polymers, like PVP, PVP is soluble in water and most organic solvents, and has low toxicity and good physiological compatibility.
The tissue coloring agent comprises polyvinylpyrrolidone iodine and iodine salt compound. PVP energy and I 2 Form complex PVP-I, the product is stable, non-irritant, completely water soluble and free I 2 And (4) effectively preserving. Free iodine makes the esophagus epithelium contain glycogen to be brown, and the tumor and the xenobiotic parts show slight or no staining due to low glycogen content. Based on the principle, the purpose of staining is achieved, the range of lesions is displayed, and clinical marking of the lesions is guided. And free I 2 After the consumption, iodine in the PVP-I complex is supplemented in time, and the content of effective iodine simple substances is ensured.
The purpose of adding a proper amount of iodine salt into the tissue staining agent is mainly to ensure that PVP and I are mixed 2 Better binding and more stable product.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 1 to 3 parts of polyvinylpyrrolidone iodine and 0.5 to 0.8 part of iodized salt.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 1.5 to 2.5 parts of polyvinylpyrrolidone iodine and 0.5 to 0.7 part of iodized salt.
In one or more embodiments of the present invention, the iodine salt is potassium iodide, sodium iodide.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 1.8 to 2.2 parts of polyvinylpyrrolidone iodine and 0.6 to 0.7 part of potassium iodide.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 2 parts of polyvinylpyrrolidone iodine and 0.65 part of potassium iodide.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 1.8 to 2.2 parts of polyvinylpyrrolidone iodine and 0.55 to 0.65 part of sodium iodide.
In one or more embodiments of the present invention, the tissue stain comprises the following components in parts by weight: 2 parts of polyvinylpyrrolidone iodine and 0.6 part of sodium iodide.
In a second aspect of the present invention, there is provided a method for preparing the tissue stain for endoscopic screening of cancer, including: uniformly mixing polyvinylpyrrolidone, iodine simple substance, iodized salt and solvent according to the weight part ratio to obtain the tissue coloring agent.
In one or more embodiments of the invention, the solvent is water.
Advantageous effects
The staining agent simultaneously satisfies the effect of prompting early esophageal cancer by utilizing the classical principle of reaction of iodine solution and glycogen for color development, and the PVP (polyvinyl pyrrolidone) high polymer material is innovatively added, so that the staining agent has obvious effect and mild action, and mucous membrane stimulation symptoms caused by a strong oxidant iodine simple substance are avoided.
Drawings
Fig. 1 is a diagram showing a biological sample 1 stained with the tissue stain of example 1.
FIG. 2 is a real diagram of a biological sample 1 dyed with Lugol's solution at a content of 1%.
Fig. 3 is a diagram showing a biological sample 2 after being stained with the tissue stain of example 2.
FIG. 4 is a real object diagram of the biological sample 2 dyed with 1% Lugol's solution.
Fig. 5 is a diagram showing a biological sample 3 after being stained with the tissue stain of example 3.
FIG. 6 is a real object diagram of the biological sample 3 dyed with 1% Lugol's solution.
Fig. 7 is a diagram showing a biological sample 4 stained with the tissue stain of example 4.
FIG. 8 is a real image of a biological sample dyed in Lugol's solution at a content of 1% in 4%.
Fig. 9 is a diagram showing a biological sample 5 stained with the tissue stain of example 5.
FIG. 10 is a real image of biological sample 5 dyed in Lugol's solution (1%).
Fig. 11 is a diagram showing a biological sample 6 after being stained with the tissue stain of example 6.
FIG. 12 is a drawing showing a biological sample 6 stained with Lugol's solution (content: 1%).
Fig. 13 is a diagram showing a biological sample 7 stained with the tissue stain of example 7.
FIG. 14 is a real object diagram of the biological sample 7 dyed with 1% Lugol's solution.
Fig. 15 is a diagram showing a biological sample 8 stained with the tissue stain of example 8.
FIG. 16 is a real object diagram of the biological sample 8 dyed with 1% Lugol's solution.
Fig. 17 is a diagram showing a biological sample 9 stained with the tissue stain of example 9.
FIG. 18 is a real image of a biological sample 9 dyed with Lugol's solution at a content of 1%.
Fig. 19 is a schematic diagram of dissecting esophagus and gastric mucosa after mouse a01 is subjected to intragastric lavage for 2 hours by using physiological saline.
FIG. 20 is a schematic diagram of dissecting esophagus and gastric mucosa after mouse A02 is subjected to intragastric lavage with normal saline for 2 h.
Fig. 21 is a schematic diagram of dissecting the esophagus and gastric mucosa after mouse a03 is subjected to intragastric administration with physiological saline for 1 d.
Fig. 22 is a schematic diagram of dissecting the esophagus and gastric mucosa after mouse a04 is subjected to gastric lavage treatment with physiological saline for 1 d.
FIG. 23 is a schematic diagram of dissecting esophagus and gastric mucosa after mouse A05 is treated for 3 days by lavage with physiological saline.
FIG. 24 is a schematic diagram of dissecting the esophagus and gastric mucosa of a mouse A06 after gastric lavage with physiological saline for 3 days.
Fig. 25 is a schematic diagram of dissected esophageal and gastric mucosa of mouse B01 after 2h of intragastric gavage treatment with the tissue stain of example 1.
Fig. 26 is a schematic diagram of dissecting esophagus and gastric mucosa of mouse B02 after 2h of intragastric administration with the tissue stain of example 1.
Fig. 27 is a schematic diagram of dissected esophageal and gastric mucosa of mouse B03 after intragastric administration for 1d with the tissue stain of example 1.
Fig. 28 is a schematic diagram of dissected esophageal and gastric mucosa of mouse B04 after intragastric treatment for 1d with the tissue stain of example 1.
Fig. 29 is a schematic diagram of dissecting the esophagus and gastric mucosa 3d after mouse B05 was gavaged with the tissue stain of example 1.
Fig. 30 is a schematic diagram of dissected esophagus and gastric mucosa of mouse B06 after 3d of gavage treatment with the tissue stain of example 1.
FIG. 31 is a schematic diagram showing the dissected esophagus and gastric mucosa after the gavage treatment of mouse A01 using a 1% Lugol's solution for 2 h.
FIG. 32 is a schematic diagram showing dissected esophageal and gastric mucosa after lavage of mouse A02 with 1% Lugol's solution for 2 h.
FIG. 33 is a schematic view of dissected esophagus and gastric mucosa of mouse A03 after intragastric treatment with 1% Lugol's solution.
FIG. 34 is a schematic view of dissected esophageal and gastric mucosa after gastric lavage of mouse A04 with 1% Lugol's solution for 1 d.
FIG. 35 is a schematic view of the dissected esophagus and gastric mucosa after lavage of mouse A05 with 1% Lugol's solution for 3 d.
FIG. 36 is a schematic view of the dissected esophagus and gastric mucosa after lavage of mouse A06 with a solution of 1% Lugol's for 3 d.
Fig. 37 shows normal esophageal mucosa under endoscope.
FIG. 38 is a schematic diagram showing endoscopic esophageal precancer coloration after Lugol's solution spraying (lightly stained part is a diseased tissue).
FIG. 39 is a sample of esophageal precancer in vitro without stain sprayed.
FIG. 40 is a schematic view of the sample of FIG. 39 sprayed with the tissue stain of the present invention, showing the sample of early esophageal cancer in vitro (the middle lightly stained lesion tissue).
FIG. 41 is a schematic diagram of the specimen of FIG. 39 sprayed with a conventional iodine staining reagent to obtain an in vitro esophageal precancer specimen (the middle lightly stained lesion tissue).
FIG. 42 is an unstained esophageal lesion specimen.
FIG. 43 is a specimen of esophageal lesions stained with the tissue stain of example 10.
FIG. 44 is the tissue stain stained esophageal lesion specimen of example 11.
FIG. 45 is the tissue stain stained esophageal lesion specimen of example 12.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure of the present invention.
PVP: brand name: qlodine Prills,2821418916, K16-K18, average molecular weight 8000.
I 2 : brand name: GENERAL-REAGENT, molecular weight 253.81, 99.8% or more, CAS 7553-56-2.
KI: brand name: GENERAL-REAGENT, AR ≥ 99%, MW =166, CAS 7681-11-0.
NaI: brand name: innochem, A24635-500G, AR,99%.
Example 1
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 3g of NaI, placing in a brown glass bottle;
step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 2
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 2.5g of NaI, placing in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 3
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 2g of NaI, placing in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 4
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 3.5g of NaI, placing in a brown glass bottle;
step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 5
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 4g of NaI, placing in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 6
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 3.3g of KI, and placing the KI in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 7
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 3g of KI, placing the KI in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 8
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 2.5g of KI, placing the KI in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Example 9
A preparation method of a tissue stain for endoscopic screening of canceration specifically comprises the following steps:
step one, weighing 5g PVP and 5g I by an electronic scale 2 And 4g of KI, placing the KI in a brown glass bottle;
and step two, weighing 500ml of deionized water by using a measuring cup, shaking and uniformly mixing until the solute is completely dissolved, and storing the solution in a shade place to obtain the water-soluble film.
Tissue stain concentration test:
example 10
PVP and I 2 And KI is added into the deionized water according to the weight ratio in the embodiment 6 to prepare a tissue coloring agent, wherein the PVP-I weight concentration in the tissue coloring agent is 2 percent, and the mass concentration of KI is0.65%。
Example 11
The tissue stain is prepared according to the preparation method, wherein the PVP-I weight concentration is 4% and the KI mass concentration is 0.65%.
Example 12
The tissue stain is prepared according to the preparation method, wherein the PVP-I weight concentration is 6%, and the KI mass concentration is 0.65%.
The tissue stain of examples 10-12 was stained with the same esophageal lesion specimen, fig. 42 is an unstained esophageal lesion specimen, fig. 43 is an esophageal lesion specimen stained with the tissue stain of example 10, fig. 44 is an esophageal lesion specimen stained with the tissue stain of example 11, and fig. 45 is an esophageal lesion specimen stained with the tissue stain of example 12. The results show that: the PVP-I weight concentration of 2% can obviously outline the lesion boundary, the PVP-I weight concentration of 4% and the dyeing effect of 6% concentration have no obvious difference relative to 2%.
Dyeing effect verification experiment
For the dyeing effect of verifying novel dyeing agent, this application has designed clinical trial, through dyeing human esophagus ESD postoperative sample, compares the dyeing effect of novel dyeing agent and traditional Lugol's liquid.
The verification method comprises the following steps: and spraying the tissue staining agent on a human esophagus ESD postoperative sample, taking a picture by fixing a focal length by using a fixed camera after staining, and analyzing by using Image analysis software Image J after taking the picture. And then eluting by using a vitamin C solution, spraying the traditional Lugol's solution on the human esophagus ESD postoperative specimen after the elution is finished, and analyzing by using Image analysis software Image J after photographing. The order of use of Lugol's solution and the tissue stain of the present application can be interchanged.
The Image analysis software Image J is used for outlining the abnormal dyeing area, and the size difference of the lesion is large, so that the abnormal dyeing area is difficult to directly compare with the abnormal dyeing area, so that the difference ratio = (novel dyeing agent-iodine dyeing agent)/iodine dyeing agent is used for carrying out statistical analysis, and the dyeing effect of the tissue dyeing agent is compared with that of the traditional Lugol's solution. The tissue stain of the present application makes normal tissue appear dark brown, and diseased regions are lightly stained/not stained. Lugol's solution makes normal tissue appear dark brown to brown, and the diseased part is lightly stained/not stained.
Lesion area displayed by tissue stain and Lugol's liquid on esophagus staining
TABLE 1
The results of the study in Table 1 show that the tissue stain of the present invention has similar definition of the stained boundary of the esophagus to the conventional Lugol's fluid, as can be seen from a comparison of FIGS. 1-18. The stained area was measured by Imaje J software and tested using SPSS software using differential test method, showing P =0.053 (> 0.05), indicating that there was no difference between the two reagents in the "lesion area" outlined. The tissue staining agent has a staining effect no less than that of the conventional Lugol's solution, and is helpful for an endoscopist to identify early esophageal tumors.
Biosafety test
In order to verify the safety and the irritation of the novel staining agent, the unit designs an animal experiment.
The test protocol was as follows: 18 KM mice were randomly divided into 3 groups of 6 mice each, and esophageal perfusion was performed with physiological saline, 1% tissue stain (tissue stain prepared in example 1), and l% Lugol's solution, respectively. After successful gavage, 2 mice were sacrificed by cervical dislocation each time according to the time (2 hours, 1 day, 3 days) and the mice esophagus and stomach were obtained. Cutting off esophagus and stomach, turning the mucosa outwards, fixing and spreading with pin, observing and shooting, measuring the damage length of esophagus and stomach surface with ruler, and calculating the damage index (UI) of gastric mucosa. The gastric mucosal lesion index of each group of mice was calculated according to the Guth method (i.e., the sum of the gastric mucosal lesion scores of each mouse in each group was added). The punctate bleeding is 1 minute, the linear bleeding length is less than 1mm and is 2 minutes,the content of the waste water is 3 minutes, 4 minutes and 5 minutes when the diameter is larger than 4 mm; a value of 2[ 2 ], [1 ] to 3 ] having a width of 2mm]。
Tissue stain and Lugol's solution of example 1 dissected gastric mucosal injury index (UI value) after gavage of mice
TABLE 2
The research result shows that the 3 groups of mice have no obvious abnormality of activity state, food intake and spirit after gastric lavage and have no abnormal death within 3 days. The degree of redness and swelling of the gastric mucosa of the mice reached the highest in the acute inflammatory phase (1 day), the average value of UI in the 1% tissue staining agent lavage group was lower than that in the Lugol's solution lavage group, and the mice gradually relieved at 3 days (the research results are shown in the following Table 2). The above results demonstrate the safety of the novel stain and the irritation of the oesophageal-gastric mucosa is less than that of Lugol's solution.
In addition, in terms of formula, the components contained in the tissue stain are stable and completely water-soluble, the irritation is extremely small, the safety is higher theoretically, and the mucosa irritation symptom caused by a strong oxidant iodine simple substance is avoided.
In conclusion, the tissue stain disclosed by the invention has the advantages of wide applicable patient population, high effectiveness, simplicity in operation, high safety and small stimulation. Therefore, the invention effectively overcomes various defects in the prior art and has high industrial utilization value.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Those skilled in the art can modify or change the above-described embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. The tissue stain for endoscopic screening of canceration is characterized by comprising the following components in parts by weight: 1 to 4 parts of polyvinylpyrrolidone iodine and 0.5 to 1 part of iodized salt.
2. The tissue stain of claim 1, comprising the following components in parts by weight: 1 to 3 parts of polyvinylpyrrolidone iodine and 0.5 to 0.8 part of iodized salt.
3. The tissue stain of claim 1, comprising the following components in parts by weight: 1.5 to 2.5 parts of polyvinylpyrrolidone iodine and 0.5 to 0.7 part of iodized salt.
4. The tissue coloring agent according to any one of claims 1 to 3, wherein the iodine salt is potassium iodide or sodium iodide.
5. The tissue stain of claim 4, comprising the following components in parts by weight: 1.8 to 2.2 parts of polyvinylpyrrolidone iodine and 0.6 to 0.7 part of potassium iodide.
6. The tissue stain of claim 5, comprising the following components in parts by weight: 2 parts of polyvinylpyrrolidone iodine and 0.65 part of potassium iodide.
7. The tissue stain of claim 4, comprising the following components in parts by weight: 1.8 to 2.2 parts of polyvinylpyrrolidone iodine and 0.55 to 0.65 part of sodium iodide.
8. The tissue stain of claim 7, comprising the following components in parts by weight: 2 parts of polyvinylpyrrolidone iodine and 0.6 part of sodium iodide.
9. The method for preparing a tissue stain for endoscopic screening for cancer according to any one of claims 1 to 8, comprising: uniformly mixing polyvinylpyrrolidone, iodine simple substance, iodized salt and solvent to obtain the tissue coloring agent.
10. The method of claim 9, wherein the solvent is water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211057928.4A CN115337410A (en) | 2022-08-30 | 2022-08-30 | Tissue staining agent for endoscopic screening of canceration and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211057928.4A CN115337410A (en) | 2022-08-30 | 2022-08-30 | Tissue staining agent for endoscopic screening of canceration and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115337410A true CN115337410A (en) | 2022-11-15 |
Family
ID=83956842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211057928.4A Pending CN115337410A (en) | 2022-08-30 | 2022-08-30 | Tissue staining agent for endoscopic screening of canceration and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115337410A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103720713A (en) * | 2013-12-18 | 2014-04-16 | 深圳市安多福消毒高科技股份有限公司 | High-complexation iodine and preparation method thereof |
CN104013573A (en) * | 2014-06-25 | 2014-09-03 | 山西神龙天翼科技有限公司 | High-content liquid povidone-iodine |
CN104083397A (en) * | 2014-07-18 | 2014-10-08 | 武汉品瑞医学科技有限公司 | Compound polyninylpyrrolidone sterilizing agent and preparation method thereof |
CN110201190A (en) * | 2019-06-27 | 2019-09-06 | 施瑞华 | A kind of coloring agent and preparation method thereof for cancer of the esophagus early diagnosis |
-
2022
- 2022-08-30 CN CN202211057928.4A patent/CN115337410A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103720713A (en) * | 2013-12-18 | 2014-04-16 | 深圳市安多福消毒高科技股份有限公司 | High-complexation iodine and preparation method thereof |
CN104013573A (en) * | 2014-06-25 | 2014-09-03 | 山西神龙天翼科技有限公司 | High-content liquid povidone-iodine |
CN104083397A (en) * | 2014-07-18 | 2014-10-08 | 武汉品瑞医学科技有限公司 | Compound polyninylpyrrolidone sterilizing agent and preparation method thereof |
CN110201190A (en) * | 2019-06-27 | 2019-09-06 | 施瑞华 | A kind of coloring agent and preparation method thereof for cancer of the esophagus early diagnosis |
Non-Patent Citations (1)
Title |
---|
刘刚,王启文,李沛,曲明江,张晓凯: "食管癌术前术中转移淋巴结显像的临床研究", 实用肿瘤学杂志 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jamadar et al. | Preparation and evaluation of herbal gel formulation | |
CN110891552B (en) | Enteric hard capsule | |
CN107238524B (en) | improved special dyeing diagnostic solution | |
EP3015111B1 (en) | Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease | |
CN108619519A (en) | Local minocycline composition and its application method | |
CN100528155C (en) | Nanometer berberine hydrochloride emulsion and its preparation process | |
CN107837276A (en) | The pharmaceutical composition being locally administered | |
CN101491497A (en) | Toltrazuril suspension preparation capable of being effectively uniformly dispersed in water and preparation method thereof | |
CN107837275A (en) | The pharmaceutical composition being locally administered | |
CN115337410A (en) | Tissue staining agent for endoscopic screening of canceration and preparation method thereof | |
Pecora et al. | Barrier effect and wound healing activity of the medical device REF-FTP78 in the treatment of gastroesophageal reflux disease | |
CN110801433A (en) | Targeted pharmaceutical composition loaded with amphotericin B and adriamycin together and application thereof | |
CN111184876A (en) | Alimentary canal mucous membrane coloring agent, preparation method and application thereof | |
CN104606085B (en) | A kind of chlorhexidine acetate nano-emulsion gargle of antibacterial and preparation method thereof | |
Wang et al. | Dual‐Fuel Propelled Nanomotors with Two‐Stage Permeation for Deep Bacterial Infection in the Treatment of Pulpitis | |
CN110201190A (en) | A kind of coloring agent and preparation method thereof for cancer of the esophagus early diagnosis | |
CN101664370A (en) | Eriocaulon henryanum Ruhl P.E. and application thereof in cosmetics | |
CN104406835A (en) | Indigo carmine colorant as well as preparation method and applications thereof | |
JP2004502704A (en) | Methylene blue diagnostic agent and diagnostic method for detecting epithelial cancer | |
CN112137940B (en) | Compound sugarcane leaf toothpaste and preparation method thereof | |
WO2018096161A1 (en) | Solid oral composition containing dyes | |
CN102600484A (en) | Application of shikonin serving as endoscope staining agent, and endoscope staining composition | |
Shubha et al. | Formulation and evaluation of slow releasing mouth dissolving films from Emblica officinalis fruit for prevention of dental caries | |
CN106699925B (en) | A kind of molten type chitosan-bismuth of acid and its preparation method and application | |
KR20200140728A (en) | Coating composition for applying inkjet printing thereto to form marked preparation, preparation marked with aqueous ink, and method for producing marked preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |